U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C27H30Cl2O6.H2O
Molecular Weight 539.445
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MOMETASONE FUROATE MONOHYDRATE

SMILES

O.[H][C@@]12C[C@@H](C)[C@](OC(=O)C3=CC=CO3)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]4(Cl)[C@@]2([H])CCC5=CC(=O)C=C[C@]45C

InChI

InChIKey=AQCCVUHZMIMSIB-HRVPQZBTSA-N
InChI=1S/C27H30Cl2O6.H2O/c1-15-11-19-18-7-6-16-12-17(30)8-9-24(16,2)26(18,29)21(31)13-25(19,3)27(15,22(32)14-28)35-23(33)20-5-4-10-34-20;/h4-5,8-10,12,15,18-19,21,31H,6-7,11,13-14H2,1-3H3;1H2/t15-,18+,19+,21+,24+,25+,26+,27+;/m1./s1

HIDE SMILES / InChI

Molecular Formula C27H30Cl2O6
Molecular Weight 521.429
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 8 / 8
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019796s026lbl.pdf

Mometasone is a medium-potency synthetic corticosteroid with antiinflammatory, antipruritic, and vasoconstrictive properties. Studies in asthmatic patients have demonstrated that mometasone provides a favorable ratio of topical to systemic activity due to its primary local effect along with the extensive hepatic metabolism and the lack of active metabolites. Though effective for the treatment of asthma, glucocorticoids do not affect asthma symptoms immediately. Maximum improvement in symptoms following inhaled administration of mometasone furoate may not be achieved for 1 to 2 weeks or longer after starting treatment. When glucocorticoids are discontinued, asthma stability may persist for several days or longer. Mometasone has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor which is approximately 12 times that of dexamethasone, 7 times that of triamcinolone acetonide, 5 times that of budesonide, and 1.5 times that of fluticasone. Mometasone inhaler is indicated for the maintenance treatment of asthma as prophylactic therapy. The nasal spray is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis. ELOCON Lotion (Mometasone) is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ELOCON

Approved Use

ELOCON Lotion is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients ≥12 years of age.

Launch Date

5.47171205E11
Preventing
ASMANEX

Approved Use

ASMANEX TWISTHALER is a corticosteroid indicated for: • Maintenance treatment of asthma as prophylactic therapy in patients 4 years of age and older.

Launch Date

1.11205443E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
183 pg/mL
320 μg 1 times / day steady-state, respiratory
dose: 320 μg
route of administration: Respiratory
experiment type: STEADY-STATE
co-administered:
MOMETASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
7.56 pg/mL
100 μg single, nasal
dose: 100 μg
route of administration: Nasal
experiment type: SINGLE
co-administered:
MOMETASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1560 pg × h/mL
320 μg 1 times / day steady-state, respiratory
dose: 320 μg
route of administration: Respiratory
experiment type: STEADY-STATE
co-administered:
MOMETASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
92 pg × h/mL
100 μg single, nasal
dose: 100 μg
route of administration: Nasal
experiment type: SINGLE
co-administered:
MOMETASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
19.24 h
100 μg single, nasal
dose: 100 μg
route of administration: Nasal
experiment type: SINGLE
co-administered:
MOMETASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1.5%
MOMETASONE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.1 % 1 times / day steady, topical
Recommended
Dose: 0.1 %, 1 times / day
Route: topical
Route: steady
Dose: 0.1 %, 1 times / day
Sources:
unhealthy, 0.5 - 2 yeas
n = 63
Health Status: unhealthy
Condition: dermatoses
Age Group: 0.5 - 2 yeas
Sex: unknown
Population Size: 63
Sources:
Other AEs: Glucocorticoid decreased, Skin and subcutaneous conditions NEC...
Other AEs:
Glucocorticoid decreased (1 patient)
Skin and subcutaneous conditions NEC (1 patient)
Skin bacterial infection (1 patient)
Sources:
0.1 % 1 times / day steady, topical
Recommended
Dose: 0.1 %, 1 times / day
Route: topical
Route: steady
Dose: 0.1 %, 1 times / day
Sources:
unhealthy, adult
n = 812
Health Status: unhealthy
Condition: dermatoses
Age Group: adult
Sex: unknown
Population Size: 812
Sources:
Other AEs: Pruritus, Skin atrophy...
Other AEs:
Pruritus (4.8%)
Skin atrophy (4.8%)
Tingling (4.8%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Glucocorticoid decreased 1 patient
0.1 % 1 times / day steady, topical
Recommended
Dose: 0.1 %, 1 times / day
Route: topical
Route: steady
Dose: 0.1 %, 1 times / day
Sources:
unhealthy, 0.5 - 2 yeas
n = 63
Health Status: unhealthy
Condition: dermatoses
Age Group: 0.5 - 2 yeas
Sex: unknown
Population Size: 63
Sources:
Skin and subcutaneous conditions NEC 1 patient
0.1 % 1 times / day steady, topical
Recommended
Dose: 0.1 %, 1 times / day
Route: topical
Route: steady
Dose: 0.1 %, 1 times / day
Sources:
unhealthy, 0.5 - 2 yeas
n = 63
Health Status: unhealthy
Condition: dermatoses
Age Group: 0.5 - 2 yeas
Sex: unknown
Population Size: 63
Sources:
Skin bacterial infection 1 patient
0.1 % 1 times / day steady, topical
Recommended
Dose: 0.1 %, 1 times / day
Route: topical
Route: steady
Dose: 0.1 %, 1 times / day
Sources:
unhealthy, 0.5 - 2 yeas
n = 63
Health Status: unhealthy
Condition: dermatoses
Age Group: 0.5 - 2 yeas
Sex: unknown
Population Size: 63
Sources:
Pruritus 4.8%
0.1 % 1 times / day steady, topical
Recommended
Dose: 0.1 %, 1 times / day
Route: topical
Route: steady
Dose: 0.1 %, 1 times / day
Sources:
unhealthy, adult
n = 812
Health Status: unhealthy
Condition: dermatoses
Age Group: adult
Sex: unknown
Population Size: 812
Sources:
Skin atrophy 4.8%
0.1 % 1 times / day steady, topical
Recommended
Dose: 0.1 %, 1 times / day
Route: topical
Route: steady
Dose: 0.1 %, 1 times / day
Sources:
unhealthy, adult
n = 812
Health Status: unhealthy
Condition: dermatoses
Age Group: adult
Sex: unknown
Population Size: 812
Sources:
Tingling 4.8%
0.1 % 1 times / day steady, topical
Recommended
Dose: 0.1 %, 1 times / day
Route: topical
Route: steady
Dose: 0.1 %, 1 times / day
Sources:
unhealthy, adult
n = 812
Health Status: unhealthy
Condition: dermatoses
Age Group: adult
Sex: unknown
Population Size: 812
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [IC50 0.327 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
likely
likely
yes
unlikely (co-administration study)
Comment: ketoconazole 200 mg (as well as placebo) were given twice daily concomitantly on Days 4 to 9. Mometasone furoate plasma concentrations were <150 pcg/mL on Day 3 prior to coadministration of ketoconazole or placebo. Following concomitant administration of ketoconazole, 4 out of 12 subjects in the ketoconazole treatment group (n=12) had peak plasma concentrations of mometasone furoate >200 pcg/mL on Day 9 (211-324 pcg/mL)
Page: 22,23
PubMed

PubMed

TitleDatePubMed
Efficacy of budesonide in moderate to severe asthma.
2002 Jun
[Allergic contact eczema caused by henna tattoo].
2002 Sep-Oct
Efficacy and safety of ketotifen eye drops as adjunctive therapy to mometasone nasal spray in subjects with seasonal allergic rhinoconjunctivitis.
2003
Safety of the newer inhaled corticosteroids in childhood asthma.
2003
A prospective study on the efficacy of mometasone furoate monohydrate aqueous nasal spray on Chinese patients with allergic rhinitis.
2003 Apr
Treatment of recurrent chronic hyperplastic sinusitis with nasal polyposis.
2003 Jun
Systemic bioactivity of intranasal triamcinolone and mometasone in perennial allergic rhinitis.
2003 Mar
Intranasal steroid sprays in the treatment of rhinitis: is one better than another?
2003 Nov
Comparison of the flow properties of aqueous suspension corticosteroid nasal sprays under differing sampling conditions.
2003 Oct
Safety and tolerability of treatments for allergic rhinitis in children.
2004
State and trait anxiety in patients affected by nasal polyposis before and after medical treatment.
2004 Dec
Local and systemic administration of corticosteroids in the treatment of olfactory loss.
2004 Jan-Feb
[Elocom is the newest corticosteroid for local use].
2004 Jun
Nasal allergies and beyond: a clinical review of the pharmacology, efficacy, and safety of mometasone furoate.
2005
Effects of inhaled corticosteroids on bone.
2005 Jan
Effects of mometasone furoate on a rat allergic rhinitis model.
2005 Nov 7
Eosinophilic airway inflammation in COPD.
2006
Cough and its importance in COPD.
2006
The benefits of combined treatment with corticosteroids and long-acting beta agonists.
2006
Alternative therapies in antibiotic-resistant infection.
2006
Novel insights into the aetiology and pathophysiology of increased airway inflammation during COPD exacerbations.
2006 May 22
Future therapeutic treatment of COPD: struggle between oxidants and cytokines.
2007
Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma.
2007 Dec
Seborrhoeic dermatitis.
2007 Jul 1
Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate.
2007 Jul 25
Onset of action of azelastine nasal spray compared with mometasone nasal spray and placebo in subjects with seasonal allergic rhinitis evaluated in an environmental exposure chamber.
2007 Jul-Aug
Montelukast in the management of allergic rhinitis.
2007 Jun
The role of mometasone furoate aqueous nasal spray in the treatment of adenoidal hypertrophy in the pediatric age group: preliminary results of a prospective, randomized study.
2007 Jun
[Patient preference survey on the lack of taste and odor of Nasonex nasal spray. Which impact on compliance to treatment?].
2008
Airways inflammation and treatment during acute exacerbations of COPD.
2008
Vancomycin-induced DRESS syndrome in a female patient.
2008
New treatment options in allergic rhinitis: patient considerations and the role of ciclesonide.
2008 Apr
New approaches to managing asthma: a US perspective.
2008 Apr
Effect of allergic rhinitis on the use and cost of health services by children with asthma.
2008 Aug 30
Mometasone furoate in the management of asthma: a review.
2008 Dec
Relative oral corticosteroid-sparing effect of 7 inhaled corticosteroids in chronic asthma: a meta-analysis.
2008 Jul
[The effect of desloratadine on quality of life of patients with seasonal allergic rhinitis].
2008 May
Antibacterial activity of mometasone furoate.
2008 May
One-year treatment with mometasone furoate in chronic obstructive pulmonary disease.
2008 Nov 13
Effectiveness of twice daily azelastine nasal spray in patients with seasonal allergic rhinitis.
2008 Oct
Effect of illicit direct to consumer advertising on use of etanercept, mometasone, and tegaserod in Canada: controlled longitudinal study.
2008 Sep 2
Comparison of corticosteroid nasal sprays in relation to concomitant use and cost of other prescription medications to treat allergic rhinitis symptoms: retrospective cohort analysis of pharmacy claims data.
2009
Bronchial diffusing capacity of nitric oxide is increased in patients with allergic rhinitis.
2009
Using nasal steroids to treat nasal obstruction caused by adenoid hypertrophy: does it work?
2009 Feb
Use of mometasone furoate to prevent polyp relapse after endoscopic sinus surgery.
2009 Mar
Twelve years' experience with direct-to-consumer advertising of prescription drugs in Canada: a cautionary tale.
2009 May 27
Treatment of postviral olfactory loss with glucocorticoids, Ginkgo biloba, and mometasone nasal spray.
2009 Oct
Drugs associated with more suicidal ideations are also associated with more suicide attempts.
2009 Oct 2
Alitretinoin--its use in intractable hand eczema and other potential indications.
2009 Sep 21
Allergic contact dermatitis to inhalation corticosteroids.
2010 Jan-Feb
Patents

Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Can also be used as inhalation powder http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021067s013lbl.pdf
Apply a few drops to the affected skin areas once daily and massage lightly until it disappears.
Route of Administration: Topical
Mac-1 expression and human eosinophil migration were effectively downregulated by preincubation with Mometasone at 1, 10 and 100 nM
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:57:04 UTC 2023
Edited
by admin
on Fri Dec 15 15:57:04 UTC 2023
Record UNII
MTW0WEG809
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MOMETASONE FUROATE MONOHYDRATE
GREEN BOOK   MI   ORANGE BOOK   VANDF   WHO-DD  
Common Name English
NASONEX
Brand Name English
Mometasone furoate monohydrate [WHO-DD]
Common Name English
MOMETASONE FUROATE MONOHYDRATE [VANDF]
Common Name English
MOMETASONE FUROATE MONOHYDRATE [EP MONOGRAPH]
Common Name English
PREGNA-1,4-DIENE-3,20-DIONE, 9,21-DICHLORO-17-((2-FURANYLCARBONYL)OXY)-11-HYDROXY-16-METHYL-, HYDRATE (1:1), (11.BETA.,16.ALPHA.)-
Common Name English
MOMETASONE FUROATE MONOHYDRATE [GREEN BOOK]
Common Name English
RYALTRIS COMPONENT MOMETASONE FUROATE MONOHYDRATE
Brand Name English
PREGNA-1,4-DIENE-3,20-DIONE, 9,21-DICHLORO-17-((2-FURANYLCARBONYL)OXY)-11-HYDROXY-16-METHYL-, (11.BETA.,16.ALPHA.)-MONOHYDRATE
Common Name English
MOMETASONE FUROATE HYDRATE [JAN]
Common Name English
MOMETASONE FUROATE MONOHYDRATE [MI]
Common Name English
MOMETASONE FUROATE MONOHYDRATE [ORANGE BOOK]
Common Name English
MOMETASONE FUROATE HYDRATE
JAN  
Common Name English
MOMETASONE FUROATE MONOHYDRATE COMPONENT OF RYALTRIS
Brand Name English
MOMETASONE FUROATE (AS MONOHYDRATE)
Common Name English
Classification Tree Code System Code
CFR 21 CFR 524.1610
Created by admin on Fri Dec 15 15:57:04 UTC 2023 , Edited by admin on Fri Dec 15 15:57:04 UTC 2023
Code System Code Type Description
DRUG BANK
DBSALT001244
Created by admin on Fri Dec 15 15:57:04 UTC 2023 , Edited by admin on Fri Dec 15 15:57:04 UTC 2023
PRIMARY
CAS
141646-00-6
Created by admin on Fri Dec 15 15:57:04 UTC 2023 , Edited by admin on Fri Dec 15 15:57:04 UTC 2023
PRIMARY
SMS_ID
100000137366
Created by admin on Fri Dec 15 15:57:04 UTC 2023 , Edited by admin on Fri Dec 15 15:57:04 UTC 2023
PRIMARY
DAILYMED
MTW0WEG809
Created by admin on Fri Dec 15 15:57:04 UTC 2023 , Edited by admin on Fri Dec 15 15:57:04 UTC 2023
PRIMARY
ChEMBL
CHEMBL1161
Created by admin on Fri Dec 15 15:57:04 UTC 2023 , Edited by admin on Fri Dec 15 15:57:04 UTC 2023
PRIMARY
RXCUI
153374
Created by admin on Fri Dec 15 15:57:04 UTC 2023 , Edited by admin on Fri Dec 15 15:57:04 UTC 2023
PRIMARY RxNorm
FDA UNII
MTW0WEG809
Created by admin on Fri Dec 15 15:57:04 UTC 2023 , Edited by admin on Fri Dec 15 15:57:04 UTC 2023
PRIMARY
MERCK INDEX
m7597
Created by admin on Fri Dec 15 15:57:04 UTC 2023 , Edited by admin on Fri Dec 15 15:57:04 UTC 2023
PRIMARY Merck Index
PUBCHEM
9893453
Created by admin on Fri Dec 15 15:57:04 UTC 2023 , Edited by admin on Fri Dec 15 15:57:04 UTC 2023
PRIMARY
EPA CompTox
DTXSID60931149
Created by admin on Fri Dec 15 15:57:04 UTC 2023 , Edited by admin on Fri Dec 15 15:57:04 UTC 2023
PRIMARY
EVMPD
SUB75332
Created by admin on Fri Dec 15 15:57:04 UTC 2023 , Edited by admin on Fri Dec 15 15:57:04 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
ANHYDROUS->SOLVATE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY